Leukemic transformation in myelofibrosis with myeloid metaplasia: A single-institution experience with 91 cases

Blood

Volumn 105, Issue 3, 2005, Pages 973-977

  Mesa, Ruben A ^a,b   Li, Chin Yang ^a   Ketterling, Rhett P ^a   Schroeder, Georgene S ^a   Knudson, Ryan A ^a   Tefferi, Ayalew ^a  

^a Cancer Center Statistics Unit   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; BUSULFAN; CORE BINDING FACTOR; CYTARABINE; ETOPOSIDE; GEMTUZUMAB OZOGAMICIN; MELPHALAN; MITOXANTRONE; TIPIFARNIB; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER CLASSIFICATION; CANCER MORTALITY; CANCER SURVIVAL; CHEMOTHERAPY; CHROMOSOME 5; CHROMOSOME 7; CHROMOSOME ABERRATION; CONTROLLED STUDY; CYTOGENETICS; FEMALE; GENETIC TRANSFORMATION; HUMAN; HUMAN TISSUE; KARYOTYPE; LEUKEMIA; MAJOR CLINICAL STUDY; MALE; MYELOFIBROSIS; MYELOID METAPLASIA; PRIORITY JOURNAL; REMISSION; SOCIAL SUPPORT; TREATMENT OUTCOME;

EID: 12844284481     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2004-07-2864     Document Type: Article

References (20)

1. Passamonti F, Malabarba L, Orlandi E, et al. Polycythemia vera in young patients: a study on the long-term risk of thrombosis, myelofibrosis and leukemia. Haematologica. 2003;88:13-18.
2. Cervantes F, Alvarez-Larran A, Talarn C, Gomez M, Montserrat E. Myelofibrosis with myeloid metaplasia following essential thrombocythaemia: actuarial probability, presenting characteristics and evolution in a series of 195 patients. Br J Haematol. 2002;118:786-790.
3. Tefferi A. Myelofibrosis with myeloid metaplasia. N Engl J Med. 2000;342:1255-1265.
4. Koch C, Li C, Mesa R, Tefferi A. Nonhepatosplenic extrameduallry hematopoiesis: associated diseases, pathology, clinical course, and treatment. Mayo Clin Proc. 2003;78:1223-1233.
5. Cervantes F, Barosi G, Demory JL, et al. Myelofibrosis with myeloid metaplasia in young individuals: disease characteristics, prognostic factors and identification of risk groups. Br J Haematol. 1998;102:684-690.
6. Deeg HJ, Gooley TA, Flowers ME, et al. Allogeneic hematopoietic stem cell transplantation for myelofibrosis. Blood. 2003;102:3912-3918.
7. Okamura T, Kinukawa N, Niho Y, Mizoguchi H. Primary chronic myelofibrosis: clinical and prognostic evaluation in 336 Japanese patients. Int J Hematol. 2001;73:194-198.
8. Cervantes F, Tassies D, Salgado C, Rovira M, Pereira A, Rozman C. Acute transformation in nonleukemic chronic myeloproliferative disorders: actuarial probability and main characteristics in a series of 218 patients. Acta Haematol. 1991;85:124-127.
9. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100:2292-2302.
10. Dupriez B, Morel P, Demory J, et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood. 1996;88:1013-1018.
11. Tefferi A, Mesa RA, Schroeder G, Hanson CA, Li CY, Dewald GW. Cytogenetic findings and their clinical relevance in myelofibrosis with myeloid metaplasia. Br J Haematol. 2001;113:763-771.
12. Mesa RA, Silverstein MN, Jacobsen SJ, Wollan PC, Tefferi A. Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: an Olmsted County Study, 1976-1995. Am J Hematol. 1999;61:10-15.
13. Baudard M, Beauchamp-Nicoud A, Delmer A, et al. Has the prognosis of adult patients with acute myeloid leukemia improved over years? A single institution experience of 784 consecutive patients overa 16-year period. Leukemia. 1999;13:1481-1490.
14. Stasi R, Del Poeta G, Venditti A, et al. Analysis of treatment failure in patients with minimally differentiated acute myeloid leukemia (AML-MO). Blood. 1994;83:1619-1625.
15. Tallman MS, Neuberg D, Bennett JM, et al. Acute megakaryocytic leukemia: the Eastern Cooperative Oncology Group experience. Blood. 2000;96:2405-2411.
16. Tefferi A. Is hydroxyurea leukemogenic in essential thrombocythemia. Blood. 1998;92:1459-1460.
17. Barosi G, Ambrosetti A, Centra A, et al. Splenectomy and risk of blast transformation in myelofibrosis with myeloid metaplasia: Italian Cooperative Study Group on Myeloid with Myeloid Metaplasia. Blood. 1998;91:3630-3636.
18. Tefferi A, Mesa RA, Nagorney DM, Schroeder G, Silverstein MN. Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients. Blood. 2000;95:2226-2233.
19. Visani G, Finelli C, Castelli U, et al. Myelofibrosis with myeloid metaplasia: clinical and haematological parameters predicting survival in a series of 133 patients. Br J Haematol. 1990;75:4-9.
20. Barosi G, Berzuini C, Liberato LN, Costa A, Polino G, Ascari E. A prognostic classification of myelofibrosis with myeloid metaplasia. Br J Haematol. 1988;70:397-401.